Here is the latest shareholding Pattern of ZYDUS LIFESCIENCES. For more details, see the ZYDUS LIFESCIENCES financial fact sheet and ZYDUS LIFESCIENCES share price. For a sector overview, read our pharmaceuticals sector report.
No. of Mths Qtr. Ending |
3
Jun-22 |
3
Sep-22 |
3
Dec-22 |
3
Mar-23 |
3
Jun-23 |
3
Sep-23 |
3
Dec-23 |
3
Mar-24 |
||
---|---|---|---|---|---|---|---|---|---|---|
Indian Promoters | % | 74.88 | 74.98 | 74.98 | 74.98 | 74.98 | 74.98 | 74.98 | 74.98 | |
Foreign Promoters | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Total Promoters | % | 74.88 | 74.98 | 74.98 | 74.98 | 74.98 | 74.98 | 74.98 | 74.98 | |
Mutual Funds | % | 4.62 | 5.36 | 5.56 | 5.59 | 5.80 | 5.94 | 6.99 | 6.71 | |
Financial institution/Banks/Insurance | % | 7.30 | 7.31 | 7.87 | 7.67 | 7.43 | 6.86 | 5.82 | 5.74 | |
Government | % | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
FII | % | 2.86 | 2.60 | 2.51 | 3.42 | 4.04 | 4.85 | 4.99 | 5.72 | |
Other | % | 0.02 | 0.26 | 0.27 | 0.34 | 0.29 | 0.30 | 0.23 | 0.18 | |
Total Institution | % | 14.88 | 15.53 | 16.21 | 17.02 | 17.56 | 17.95 | 18.03 | 18.35 | |
Bodies Corporate | % | 0.96 | 0.95 | 0.82 | 0.71 | 0.68 | 0.65 | 0.61 | 0.61 | |
Individuals | % | 8.02 | 7.60 | 7.04 | 6.42 | 5.97 | 5.66 | 5.60 | 5.28 | |
NRIs/OCBs | % | 0.37 | 0.36 | 0.39 | 0.33 | 0.31 | 0.27 | 0.30 | 0.30 | |
ADR/GDR | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Others | % | 0.89 | 0.58 | 0.56 | 0.54 | 0.51 | 0.49 | 0.48 | 0.47 | |
Total Non-Institution | % | 10.24 | 9.49 | 8.81 | 8.00 | 7.47 | 7.07 | 6.99 | 6.66 | |
Total Public | % | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | |
Grand Total | % | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | |
Pledged Promoter Holding | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Subscriber Feature |
More Pharmaceuticals Company Shareholding Pattern: CIPLA DIVIS LABORATORIES SUN PHARMA DR. REDDYS LAB MANKIND PHARMA
Asian share benchmarks fell on Thursday as markets digested the implications of policymakers in major economies preferring to take patient approach to monetary easing amid sticky inflation.